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CASE REPORT 
Post-radiation fibrosarcoma of the breast 
M. S. Lemson, H. J. Mud, A. J. W ijnmaalen” and R. W . M. Giardt 
Departments of Surgery and fpathology, St Clara Hospital, *Department of Radiation Oncology, Dr Daniel Den Hoed 
Cancer Center, Rotter-dam, The Netherlands 
S U M  M A R Y. We  report the first case of f ibrosarcoma of stromal breast tissue occurring 11 years after breast-conserving 
therapy for breast cancer. A review of six cases of stromal malignant fibrous histiocytoma is presented, developing between 
5 years and 11 years after breast radiation. Since all cases developed in the area of boost irradiation, abandoning the booster 
dose might reduce the incidence of secondary sarcomas. Treatment of radiation-induced sarcoma should be surgical, with 
wide excisional margins. A lifelong follow-up is recommended for patients treated with breast-conserving therapy for 
primary cancer. 
INTRODUCTION 
Post-radiation sarcoma is a rare but well-recognized late 
effect of cancer therapy. Sarcomas following therapeutic 
radiation after mastectomy for breast cancer were first 
described by Warren & Sommer in 1936l and since then 
many cases were reported. 2A After the introduction of 
breast-conserving therapy for breast cancer several cases of 
angiosarcoma5~6 and malignant fibrous histiocytoma7-I1 of 
the radiated breast were described. We  report the first case 
of post-radiation stromal fibrosarcoma occurring 11 years 
after breast-conserving therapy for primary breast cancer. 
CASE REPORT 
In July 1981, a 45-year-old woman presented with a palpable 
1.5 cm mass in the upper outer quadrant of the left breast. 
Histopathological examination of the lumpectomy specimen 
showed a moderately well-differentiated adenocarcinoma of 
the breast. The margins of resection were clear of tumour. 
Subsequently, the patient underwent an axillary lymph node 
dissection. No metastases were found. Postoperatively ra- 
diation therapy was given to the breast. A total dose of 45 
Gy was given in 25 fractions over 36 days through two 
tangential fields with a photon energy of 6  MV. The pri- 
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mary site received a booster dose of 20 Gy given in 10 
fractions using 13 MeV electrons with a total treatment time 
of 18 days. Eighteen months after completing the radiation 
therapy, the breast felt firm on palpation, indicating moderate 
fibrosis. This remained unchanged during follow-up. There 
were no changes of skin appearance and the cosmetic result 
was excellent. 
In May 1992, almost 11 years after treatment for breast 
cancer, the patient returned prior to her yearly check-up be- 
cause she noticed a palpable lump at the site of the primary 
tumour. Aspiration cytology of the lesion showed no malig- 
nant cells. However, mammography had obviously changed 
showing a dense area at the site of the primary tumour, 
which was marked by clips at the operation in 1981 (Fig. 1). 
It was decided to perform an excisional biopsy June 1992, 
as recurrence of breast cancer was suspected. At histo- 
pathological examination the tumour was composed of atypi- 
cal spindle cells. No other cell types (such as multinucleated 
giant cells) were seen, so it was classified as a fibrosarcoma 
grade IT (Fig. 2). The margins of resection were clear of 
tumour. As computer tomography of thorax and abdomen 
showed no metastases, a more radical excision was advised. 
The patient underwent a left mastectomy on 25 June 1992 
with a partial resection of the thoracic wall. In cooperation 
with the reconstructive surgeon the defect was closed with a 
soft tissue Goretex-patch@* (W. L. Gore & Associates BV, 
Hertogenbosch) which was covered by a transposition graft 
of the latissimus dorsi muscle and a split skin graft. No 
residual tumour was found on histopathological examina- 
tion. Postoperatively the patient’s recovery was uneventful 
and she is alive and well 42 months after the operation. 
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Fig. 1 Mammography of May 1992 showing a dense area of 1.5 cm 
with irregular margins at the site of the haemoclips placed during the 
primary operation in 198 1. 
DISCUSSION 
In women treated for breast cancer, 40-50% of the secondary 
malignancies are carcinoma of the other breast.8~9~12 Kurtz9 
and Basco13 could not provide proof for an increased risk of 
radiation-induced carcinoma in the contralateral breast 
since contralateral secondary carcinoma is also seen in non- 
irradiated women. Other second malignancies reported after 
Fig. 2 Fibrosarcoma consisting of atypical spindle cells showing 
variation in size and shape. An arrangement in fascicle is discernible 
(H & E x 270). 
radiotherapy for breast cancer are carcinoma of the lung 
and oesophagus, sarcoma of the bone, soft tissue sarcoma 
and acute non-lymphatic leukemia.*J2J4 In 1948 Cahan 
defined four criteria for a radiation induced tumour: 
1. The tumour must have a different histology from the 
primary lesion 
2. The tumour must arise in a previously irradiated area 
3. A significant latent period (more than 5 years) must have 
elapsed after irradiation 
4. The sarcomatous nature of the post-radiation lesion must 
be histologically provenI 
The overall incidence of sarcomas that occur following 
radiation therapy for any disease is 0.2-0.3% at 10 
years. 2~9~12~1~18 There is no difference in the incidence of 
post-radiation sarcoma between orthovoltage or mega- 
voltage treatment although there seems to be a shorter 
latency period for bone sarcomas in megavoltage as com- 
pared to orthovoltage radiation (7.4 years vs 15.9 years).“,*” 
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Table All reported cases of malignant fibrous histiosarcoma and a case of fibrosarcoma after breast-conserving 
therapy for breast cancer 
Author Total dose (Gy) Sarcoma Latency (years) Treatment of sarcoma Follow-up 
Souba’O 50 MFH 9 
Delouches 
Swery 10 months, alive 
60 MFH 11 
KtlltZ” 
Surgery & chemotherapy 4 years, alive 
%O MFH 10.5 
Kurtz9 
Surgery & chemotherapy 4 years, alive 
70 MFH 5 NS 
Kurtz9 
NS, dead 
80 MFH 5.5 NS NS, dead 
Turner’ 48 MFH 5 Surgery & chemotherapy 1 year, alive 
Present report 65 FS 11 Sww 42 months, alive 
MFH = malignant fibrous histiocytoma; FS = librosarcoma; NS = not stated. 
In 1936 Warren & Sommer reported the first case of tibro- 
sarcoma occurring at the left side of the chest 24 years after 
mastectomy and radiation treatment for cancer of the breast.’ 
Since then many such cases were reported.2-4,10,17,19-21 The 
mean latency period for radiation induced sarcomas after 
mastectomy is 11 years. 17~22 However, they have been re- 
ported as late as 45 years after radiotherapy.23 
With the introduction of breast-conserving therapy, the 
risk for secondary sarcoma developed in the remaining 
tissue of the breast.* In 1987 Body et al reported the first 
angiosarcoma of the skin of the breast occurring 5 years 
after breast-conserving therapy for breast cancer.5 Since 
then, to our knowledge, only 15 cases have been reported.6 
Secondary sarcoma of the breast parenchyma occurring 
after breast-conserving therapy was first described in 
1986.% This concerned a malignant fibrous histiocytoma 2 
years and 2 months after wide excision of an infiltrating 
duct cell carcinoma followed by breast irradiation. This 
time interval is rather short for a post-radiation sarcoma 
to be induced. Only six similar cases were described, details 
of which are listed in Table.‘-” All occurred within the area 
of excision, which was boosted following whole breast irra- 
diation and at least 5 years after breast-conserving therapy 
for breast cancer. We present the first fibrosarcoma, also 
occurring within the boosted area 11 years after breast-con- 
serving therapy. In animal studies a parabolic dose-response 
curve was described for tumour induction by irradiation 
with a maximum dose beyond which tumour induction 
decreases.% As the described tumours all occured in the area 
of boost irradiation, this maximum is probably not reached 
with a dose of 65 Gy. Meta-analysis25 of the reviewed arti- 
cles showed an incidence of post-radiation sarcoma after 
mastectomy between 0.0007 and 0.003.2*3*4J7 After breast- 
conserving therapy the incidence was 0.0002-0.006.8*gJ’ 
Primary sarcoma of the breast accounts for less than 1% 
of all primary breast malignancies.‘* The mortality at 5 
years is 64% but does not increase thereafter. The mainstay 
of treatment is to gain local control through mastectomy 
with excision of the pectoral muscle. Radiation and chemo- 
therapy neither show a reduction in the rate of local recur- 
rence or metastatic disease, nor do they improve the overall 
survival.‘* Treatment of secondary sarcomas should be 
surgical and equally aggressive, as these tumours are also 
likely to have a high tendency to recur.‘g~22 Despite treat- 
ment, survival for all radiation induced sarcomas is 35% 
at 2 years compared to 60% for all primary sarcomas.1g 
Secondary sarcoma of the breast after breast-conserving 
therapy for primary cancer is a rare but serious problem. 
Every palpable lump or change on the mammography must 
be considered to be a recurrence of the primary disease or 
a secondary sarcoma until proven otherwise. Since the 
secondary stromal sarcomas described all occurred in the 
area of boost irradiation, this seems to be an area of in- 
creased risk. The occurrence of secondary cancer may 
decrease if the boost irradiation can be abandoned safely, 
that is, without increasing the risk on local recurrence. As 
secondary sarcomas have been reported up to 45 years after 
radiation, a life-long surveillance is advised in all patients 
treated with radiation therapy. 
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